Despite the availability of clinically approved reversible AChE inhibitors such as donepezil in the market, there is still a need for better therapeutics for AD due to the adverse side-effects associated with available drugs and the fact that none of the currently available AChE inhibitors showed any improvement of cognitive functions [5,6]. Here, ACHE is linked to Alzheimer disease.